The Society of Nuclear Medication and Molecular Imaging (SNMMI) and the European Affiliation of Nuclear Medication (EANM) have issued a brand new process commonplace/follow guideline for estrogen receptor imaging of breast most cancers sufferers utilizing FES PET. The usual/guideline, revealed forward of print in The Journal of Nuclear Medication, is meant to help physicians in recommending, performing, deciphering, and reporting the outcomes of 18F-FES PET research for sufferers with breast most cancers.
Greater than two million ladies worldwide are recognized with breast most cancers every year. The estrogen receptor (ER) is a major contributor to breast most cancers formation and development and, as such, is a vital goal for remedy. Roughly 70 % of breast cancers will specific ER, and the willpower of ER expression by tissue evaluation is a part of the usual of take care of these newly recognized breast most cancers.
A number of research recommend that 18F-FES PET-;which is permitted for medical use in France and the United States-;provides benefits in assessing tumor ER expression, predicting response to ER-targeted therapies, and clarifying equivocal staging and restaging leads to sufferers with ER-expressing cancers. It might even be useful in staging invasive lobular breast most cancers and low-grade ER-expressing invasive ductal cancers and, in some instances, could also be an alternative to biopsy.
The process guideline/follow commonplace contains info on widespread medical indications, process specs, affected person choice and preparation, tracer administration and imaging, and imaging interpretation and reporting. It additionally presents standardized high quality management, high quality assurance, and imaging procedures for 18F-FES PET.
“Precision, accuracy, repeatability, and reproducibility for each medical administration of sufferers and for the usage of 18F-FES in multicenter trials is essential,” emphasize the authors. “The provision of a standardized imaging process will assist to advertise the suitable use of 18F-FES PET and improve subsequent analysis.”
SNMMI/EANM periodically outline new requirements/tips for nuclear drugs follow to assist advance the science of nuclear drugs and to ship efficient and protected medical care to sufferers. Every commonplace/guideline, representing a coverage assertion by the SNMMI/EANM, undergoes an intensive consensus course of through which it’s subjected to in depth evaluate.
This text was revealed on-line in December 2023.
Supply:
Journal reference:
Mankoff, D., et al. (2023). Abstract: SNMMI Process Customary/EANM Observe Guideline for Estrogen Receptor Imaging of Sufferers with Breast Most cancers Utilizing 16α-[18F]Fluoro-17β-Estradiol PET. Journal of Nuclear Medication. doi.org/10.2967/jnumed.123.266938.
